Witty and Dekkers bemoan austerity measures, but remain tight lipped on way forward
This article was originally published in Scrip
GSK CEO, Andrew Witty, this week complained that European governments treated the purchase of life saving drugs like any other procurement exercise, while Dr Marjin Dekkers, chairman of Bayer’s management board, pointed to their failure to value innovation. However, neither company would comment on potential alternatives or action plans for cash strapped policy makers.
You may also be interested in...
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Canada has announced new restrictions on exports to help mitigate the impact of measures in the US to lower medicine prices there.
In the wake of the COVID-19 pandemic and the ensuing economic fallout, pharmaceutical companies could face a range of measures designed to cut government spending on medicines. From relaxing intellectual property rights to delaying reimbursement, In Vivo examines what might be in store for industry.